Seoul Pharma Co., Ltd (KOSDAQ:018680)
2,945.00
+5.00 (0.17%)
At close: Jan 23, 2026
Seoul Pharma Revenue
Seoul Pharma had revenue of 13.64B KRW in the quarter ending September 30, 2025, with 1.78% growth. This brings the company's revenue in the last twelve months to 52.43B, down -0.83% year-over-year. In the year 2024, Seoul Pharma had annual revenue of 53.58B with 2.14% growth.
Revenue (ttm)
52.43B
Revenue Growth
-0.83%
P/S Ratio
0.65
Revenue / Employee
304.85M
Employees
172
Market Cap
34.34B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 53.58B | 1.12B | 2.14% |
| Dec 31, 2023 | 52.46B | 2.40B | 4.80% |
| Dec 31, 2022 | 50.06B | 9.59B | 23.71% |
| Dec 31, 2021 | 40.46B | -11.77B | -22.53% |
| Dec 31, 2020 | 52.23B | -1.72B | -3.19% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Hurum | 95.37B |
| GeneBioTech Co. ,Ltd | 92.28B |
| Korean Drug | 62.21B |
| ChoA Pharmaceutical Co., LTD. | 60.50B |
| Kyung Nam Pharm | 56.18B |
| WooGene B&G | 54.77B |
| Daesung Microbiological Labs. | 25.86B |
| BIFIDO | 18.65B |